Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus MUCINEX D.
ADVIL CONGESTION RELIEF vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
NSAID/Decongestant Combination
Expectorant/Decongestant Combination